Clinical Trials Logo

Clinical Trial Summary

This is a randomized double-blind three-arm trial to evaluate two dosages of CVT-E002 against placebo in pediatric upper respiratory tract infections (URTI). It is hypothesized that CVT-E002 use at standard doses reduces the duration of URTI in children aged 3-12 years.


Clinical Trial Description

The eligible children, for whom parental consent has been obtained, will be randomized to one of three groups (standard dose, low dose, or placebo). The standard dose group will receive an oral aqueous solution using the standard dose of CVT-E002, adjusted according to the child's weight. The second group will receive an oral aqueous solution with half of the standard dose of CVT-E002, adjusted according to the child's weight, and the third group will receive a placebo as an aqueous solution of starch that does not contain any CVT-E002 or active medication, volume adjusted for the child's weight. Parents will be provided with a 3-day supply of study medication according to the randomization schedule. CVT-E002 will be administered by the parent to the child three times daily for three consecutive days following the onset of a URTI. Severity and duration of URTI will be measured using the reliable and valid Canadian Acute Respiratory Infection Flu Score (CARIFS). ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00255307
Study type Interventional
Source Afexa Life Sciences Inc
Contact
Status Completed
Phase Phase 2
Start date November 2005
Completion date April 2006

See also
  Status Clinical Trial Phase
Completed NCT03711292 - Using Behavioral Science to Reduce Inappropriate Antibiotic Use in Acute Care Settings N/A
Completed NCT01168778 - Improving Communication During Pediatric Visits for Acute Respiratory Illness N/A
Terminated NCT00187785 - Doctor-Patient Communication in Spanish N/A
Completed NCT00405509 - The Natural History of Viral Upper Respiratory Infections in Children Aged 6 to Less Than 14 Years N/A
Completed NCT00189475 - Evaluate the Potential of Montelukast to Prevent Nasal Symptomatology During Colds Phase 4
Completed NCT04468204 - Use of Novel Sinusonic Device for Prevention of Community Acquired Upper Respiratory Infection (URI) N/A
Active, not recruiting NCT05666752 - Effect of Intake of Allium Cepa L. Peel Heated Water Extract on Immunity Enhancement N/A
Suspended NCT05035420 - A Noninvasive Multimodal Biosensing Device for Screening and Monitoring Response to Treatment of Infectious Respiratory Diseases N/A
Recruiting NCT06244615 - Clinical Trial of a Mouth and Throat Rinse for the Treatment of Acute Sore Throat N/A
Completed NCT02694679 - Randomized Controlled Trial of Social Network Targeting in Honduras N/A
Completed NCT05352581 - BD Veritorâ„¢ At-Home and BD Veritorâ„¢ Professional
Active, not recruiting NCT02943551 - Dialogue Around Respiratory Illness Treatment N/A
Completed NCT01657643 - Effect of Probiotics on Health-related Quality of Life in College Students With Upper Respiratory Infections N/A
Completed NCT02110732 - Lactobacillus Rhamnosus GG in the Middle Ear and Adenoid Tonsil N/A
Completed NCT00694421 - Gas Supply, Demand and Middle Ear Gas Balance: Specific Aim 2 N/A
Completed NCT03884777 - Incidence and Risk of Influenza in Myasthenic Patients
Completed NCT00796315 - Study Evaluating the Pharmacokinetics of Doxylamine Succinate in Children Phase 1
Completed NCT00642681 - Effects of URI on Diabetic Subjects Utilizing Technosphere Insulin After a Meal Challenge Phase 2
Completed NCT00259831 - Efficacy of Cold-FX (CVT-E002) in the Prevention of Upper Respiratory Tract Infections in Healthy Adults Phase 3
Completed NCT04588376 - Improving Antibiotic Prescribing for Pediatric Respiratory Infections by Family Physicians With Peer Comparison N/A